Multimodal management of surgery- and radiation-refractory meningiomas: an analysis of the French national tumor board meeting on meningiomas cohort.
Atypical meningioma
Bevacizumab
Disease-Free Survival
Everolimus
High-grade meningioma
Malignant meningioma
Meningioma
Radiation therapy
Treatment Outcome
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
12
01
2021
accepted:
12
03
2021
pubmed:
30
3
2021
medline:
16
12
2021
entrez:
29
3
2021
Statut:
ppublish
Résumé
Meningiomas represent the most frequent tumor of the central nervous system in adults. While most meningiomas are efficiently treated by surgery and radiotherapy/radiosurgery, there is a small portion of radiation- and surgery-refractory tumors for which there is no clear recommendation for optimal management. The French National Tumor Board Meeting on Meningiomas (NTBM) offers a glimpse on the current management of such patients. We retrospectively reviewed the charts of patients presented to the multidisciplinary Meeting between 2016 and 2019. We selected patients with a progressive disease after at least two treatments, including surgery and radiotherapy. In this multicentric cohort of 86 cases, patients harbored 17 (19.8%) WHO Grade I, 48 (55.8%) WHO Grade II and 21 (24.4%) WHO Grade III tumors. The median number of treatments received before inclusion was 3 (range: 2 - 11). Following the Board Meeting, 32 patients (37.2%) received chemotherapy, 11 (12.8%) surgery, 17 (19.8%) radiotherapy, 14 (16.3%) watchful observation and 12 (13.9%) palliative care. After a mean follow-up of 13 months post-inclusion, 32 patients (37.2%) had died from their disease. The mean progression free survival was 27 months after radiotherapy, 10 months after surgery, 8.5 months after chemotherapy (Bevacizumab: 9 months - Octreotide/Everolimus: 8 months). Surgery- and radiation-refractory meningiomas represent a heterogeneous group of tumors with a majority of WHO Grade II cases. If re-irradiation and redo-surgery are not possible, bevacizumab and octreotide-everolimus appear as a valuable option in heavily pre-treated patients considering the current EANO guidelines.
Identifiants
pubmed: 33778930
doi: 10.1007/s11060-021-03741-7
pii: 10.1007/s11060-021-03741-7
doi:
Substances chimiques
Bevacizumab
2S9ZZM9Q9V
Everolimus
9HW64Q8G6G
Octreotide
RWM8CCW8GP
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
55-64Références
Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS (2020) CBTRUS statistical report primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro-Oncol 22(122):iv1–iv96
doi: 10.1093/neuonc/noaa200
Pasquier D, Bijmolt S, Veninga T, Rezvoy N, Villa S, Krengli M et al (2008) Atypical and malignant meningioma: outcome and prognostic factors in 119 irradiated patients. A multicenter, retrospective study of the Rare Cancer Network. Int J Radiat Oncol Biol Phys. 71(5):1388–1393
doi: 10.1016/j.ijrobp.2007.12.020
Durand A, Labrousse F, Jouvet A, Bauchet L, Kalamaridès M, Menei P et al (2009) WHO grade II and III meningiomas: a study of prognostic factors. J Neurooncol 95(3):367–375
doi: 10.1007/s11060-009-9934-0
Kaur G, Sayegh ET, Larson A, Bloch O, Madden M, Sun MZ et al (2014) Adjuvant radiotherapy for atypical and malignant meningiomas: a systematic review. Neuro-Oncol 16(5):628–636
doi: 10.1093/neuonc/nou025
Chamberlain MC, Barnholtz-Sloan JS (2011) Medical treatment of recurrent meningiomas. Expert Rev Neurother 11(10):1425–1432
doi: 10.1586/ern.11.38
Zouaoui S, Darlix A, Rigau V, Mathieu-Daudé H, Bauchet F, Bessaoud F et al (2018) Descriptive epidemiology of 13,038 newly diagnosed and histologically confirmed meningiomas in France: 2006–2010. Neurochirurgie 64(1):15–21
doi: 10.1016/j.neuchi.2014.11.013
Rogers CL, Perry A, Pugh S, Vogelbaum MA, Brachman D, McMillan W et al (2016) Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539. Neuro-Oncol 18(4):565–574
doi: 10.1093/neuonc/nov247
Sahm F, Schrimpf D, Stichel D, Jones DTW, Hielscher T, Schefzyk S et al (2017) DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol 18(5):682–694
doi: 10.1016/S1470-2045(17)30155-9
Biczok A, Kraus T, Suchorska B, Terpolilli NA, Thorsteinsdottir J, Giese A et al (2018) TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas. J Neurooncol 139(3):671–678
doi: 10.1007/s11060-018-2912-7
Katz LM, Hielscher T, Liechty B, Silverman J, Zagzag D, Sen R et al (2018) Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. Acta Neuropathol (Berl) 135(6):955–963
doi: 10.1007/s00401-018-1844-9
Sievers P, Hielscher T, Schrimpf D, Stichel D, Reuss DE, Berghoff AS et al (2020) CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. Acta Neuropathol (Berl) 140:409–413
doi: 10.1007/s00401-020-02188-w
Preusser M, Brastianos PK, Mawrin C (2018) Advances in meningioma genetics: novel therapeutic opportunities. Nat Rev Neurol 14(2):106–115
doi: 10.1038/nrneurol.2017.168
Abedalthagafi M, Bi WL, Aizer AA, Merrill PH, Brewster R, Agarwalla PK et al (2016) Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro-Oncol 18(5):649–655
doi: 10.1093/neuonc/nov316
Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raizer J et al (2015) Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review J Neurosurg 122(1):4–23
doi: 10.3171/2014.7.JNS131644
Peyre M, Gauchotte G, Giry M, Froehlich S, Pallud J, Graillon T et al (2018) De novo and secondary anaplastic meningiomas a study of clinical and histomolecular prognostic factors. Neuro-Oncol. 20(8):1113–1121
doi: 10.1093/neuonc/nox231
Kaley T, Barani I, Chamberlain M, McDermott M, Panageas K, Raizer J et al (2014) Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro-Oncol 16(6):829–840
doi: 10.1093/neuonc/not330
Chamberlain MC (2012) Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma. J Neurooncol 107(2):315–321
doi: 10.1007/s11060-011-0741-z
Chamberlain MC (2013) IFN-α for recurrent surgery- and radiation-refractory high-grade meningioma: a retrospective case series. CNS Oncol 2(3):227–235
doi: 10.2217/cns.13.17
Johnson DR, Kimmel DW, Burch PA, Cascino TL, Giannini C, Wu W et al (2011) Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma. Neuro-Oncol 13(5):530–535
doi: 10.1093/neuonc/nor044
Simó M, Argyriou AA, Macià M, Plans G, Majós C, Vidal N et al (2014) Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy. Cancer Chemother Pharmacol 73(5):919–923
doi: 10.1007/s00280-014-2422-z
Huang RY, Bi WL, Weller M, Kaley T, Blakeley J, Dunn I et al (2019) Proposed response assessment and endpoints for meningioma clinical trials report from the response assessment in neuro-oncology working group. Neuro-Oncol. 21(1):26–36
doi: 10.1093/neuonc/noy137
Graillon T, Sanson M, Campello C, Idbaih A, Peyre M, Peyrière H et al (2020) Everolimus and octreotide for patients with recurrent meningioma: results from the phase II CEVOREM trial. Clin Cancer Res Off J Am Assoc Cancer Res 26(3):552–557
doi: 10.1158/1078-0432.CCR-19-2109
Nayak L, Iwamoto FM, Rudnick JD, Norden AD, Lee EQ, Drappatz J et al (2012) Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol 109(1):187–193
doi: 10.1007/s11060-012-0886-4
Shih KC, Chowdhary S, Rosenblatt P, Weir AB, Shepard GC, Williams JT et al (2016) A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma. J Neurooncol 129(2):281–288
doi: 10.1007/s11060-016-2172-3
Lou E, Sumrall AL, Turner S, Peters KB, Desjardins A, Vredenburgh JJ et al (2012) Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol 109(1):63–70
doi: 10.1007/s11060-012-0861-0
Franke AJ, Skelton WP, Woody LE, Bregy A, Shah AH, Vakharia K et al (2018) Role of bevacizumab for treatment-refractory meningiomas: A systematic analysis and literature review. Surg Neurol Int 9:133
doi: 10.4103/sni.sni_264_17
Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart E et al (2016) EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol 17(9):e383-391
doi: 10.1016/S1470-2045(16)30321-7
Jenkinson MD, Javadpour M, Haylock BJ, Young B, Gillard H, Vinten J, et al. The ROAM/EORTC-1308 trial: Radiation versus Observation following surgical resection of Atypical Meningioma: study protocol for a randomised controlled trial. Trials [Internet]. 2015 Nov 14 [cited 2020 Jul 16];16. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650615/
Lin AJ, Hui C, Dahiya S, Lu H-C, Kim AH, Campian JL et al (2018) Radiologic response and disease control of recurrent intracranial meningiomas treated with reirradiation. Int J Radiat Oncol Biol Phys. 102(1):194–203
doi: 10.1016/j.ijrobp.2018.05.011
El Shafie RA, Czech M, Kessel KA, Habermehl D, Weber D, Rieken S et al (2018) Evaluation of particle radiotherapy for the re-irradiation of recurrent intracranial meningioma. Radiat Oncol Lond Engl 13(1):86
doi: 10.1186/s13014-018-1026-x